This HTML5 document contains 59 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n6http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n19http://linked.opendata.cz/resource/domain/vavai/subjekt/
n16http://linked.opendata.cz/ontology/domain/vavai/
n4http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00064211%3A_____%2F11%3A%230000101%21RIV12-MZ0-00064211/
n14http://linked.opendata.cz/resource/domain/vavai/zamer/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n15http://bibframe.org/vocab/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n5http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n9http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n11http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n7http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n18http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n12http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n8http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00064211%3A_____%2F11%3A%230000101%21RIV12-MZ0-00064211
rdf:type
skos:Concept n16:Vysledek
dcterms:description
To evaluate the efficancy and safety of dulanermin combined with paclitaxel and carboplatin and bevacizumab as first fine treatment for advanced or recurrent nonsmall cell lung cancer (NCLC). The study found that the addition of dulanermin to carboplatin and bevacizumab did not improve outcome in unselected patinets with previously untreated advanced or recurrent NSCLC To evaluate the efficancy and safety of dulanermin combined with paclitaxel and carboplatin and bevacizumab as first fine treatment for advanced or recurrent nonsmall cell lung cancer (NCLC). The study found that the addition of dulanermin to carboplatin and bevacizumab did not improve outcome in unselected patinets with previously untreated advanced or recurrent NSCLC
dcterms:title
Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer
skos:prefLabel
Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer
skos:notation
RIV/00064211:_____/11:#0000101!RIV12-MZ0-00064211
n16:predkladatel
n19:ico%3A00064211
n3:aktivita
n7:Z n7:N
n3:aktivity
N, Z(MZ00000064211)
n3:cisloPeriodika
33
n3:dodaniDat
n8:2012
n3:domaciTvurceVysledku
n6:7693028
n3:druhVysledku
n18:J
n3:duvernostUdaju
n9:S
n3:entitaPredkladatele
n4:predkladatel
n3:idSjednocenehoVysledku
225681
n3:idVysledku
RIV/00064211:_____/11:#0000101
n3:jazykVysledku
n11:eng
n3:klicovaSlova
randomised phase II study; dulanermin; combination; paclitaxel; carboplatin; bevacizumab; advanced; non-small cell lung cancer
n3:klicoveSlovo
n5:advanced n5:dulanermin n5:combination n5:carboplatin n5:bevacizumab n5:paclitaxel n5:randomised%20phase%20II%20study n5:non-small%20cell%20lung%20cancer
n3:kodStatuVydavatele
US - Spojené státy americké
n3:kontrolniKodProRIV
[988823164A9A]
n3:nazevZdroje
Journal of Clinical Oncology
n3:obor
n12:FD
n3:pocetDomacichTvurcuVysledku
1
n3:pocetTvurcuVysledku
16
n3:rokUplatneniVysledku
n8:2011
n3:svazekPeriodika
19
n3:tvurceVysledku
Juhász, E. Amler, L. Hei, Y. J. Stern, H. Zatloukal, Petr Smethurst, D. Blackhall, F. Szima, B. Pan, Y. Pujol, J. L. Ashkenazi, A. Kozielski, J. Soria, JC Márk, Z. Albert, I. Baker, N.
n3:zamer
n14:MZ00000064211
s:issn
0732-183X
s:numberOfPages
10
n15:doi
10.1200/JCO.2011.37.2623